Boehringer Ingelheim GmbH and Kyowa Kirin Co. Ltd. have announced that Boehringer Ingelheim has licensed a preclinical program from Kyowa Kirin to develop a potential first-in-class, small molecule for the treatment of autoimmune diseases.
ALX Oncology Inc. has developed ALX-2004, an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) with a topoisomerase I inhibitor payload, for treating EGFR+ cancer solid tumors.
Ascletis Pharma Inc. has selected ASC-36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor peptide agonist, as a clinical development candidate.
Alethio Therapeutics (formerly known as Alethiomics Ltd.) has emerged from stealth with two antibody-drug conjugate (ADC) programs for the treatment of myeloproliferative neoplasms (MPNs).
Interleukin 1 receptor accessory protein (IL1RAP) is a receptor that activates signaling pathways triggered by IL1α/β, IL33 and IL36α/β/γ, which are involved in several autoimmune or inflammatory disorders, including psoriasis, gout or systemic sclerosis. Innovent Biologics Co. Ltd. presented data for their anti-IL1RAP antibody IBI-3011, a fully humanized IgG1 antibody targeting IL1RAP that blocks those pathways.
A recent study published in the journal Biochemical Pharmacology has uncovered a promising new approach to prevent post-traumatic trigeminal neuropathy (PTTN) development by targeting the advanced glycation end-products receptor (RAGE).
The U.S. FDA has granted orphan drug designation to Dewpoint Therapeutics Inc.’s DPTX-3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the recent opening of Dewpoint’s IND application for DPTX-3186 earlier in October, and is the first orphan designation ever granted to a condensate-modulating therapeutic.
Zag Bio Inc. came out of stealth mode with $80 million in funding so far, including a recently closed series A financing, to develop its platform for autoimmune diseases using drugs targeted to the thymus where thymic regulatory cells are produced.
Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors reported to be useful for the treatment of cancer, infections, autoimmune diseases, cardiovascular diseases, inflammatory disorders and neurological conditions.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged dihydrofuro[3,4-f]quinazoline compounds acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.
RSS
